Last reviewed · How we verify
Chemotherapy and Radioimmunotherapy
At a glance
| Generic name | Chemotherapy and Radioimmunotherapy |
|---|---|
| Sponsor | University of Pittsburgh |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Nausea
- Hemoglobin
- Leukocytes (total WBC)
- Platelets
- Fatigue (asthenia, lethargy, malaise)
- Lymphopenia
- Diarrhea
- Pain
- Vomiting
- Anorexia
- Albumin, serum-low (hypoalbuminemia)
- Neutrophils/granulocytes (ANC/AGC)
Key clinical trials
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
- Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma (PHASE2)
- Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma (PHASE1)
- Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC
- The Optimal Radioimmunotherapy Combinations for Advanced TNBC (PHASE2)
- Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC (PHASE2)
- A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases (PHASE2)
- Radioimmunotherapy in Solid Tumors (PNRR-MCNT2-2023-12378239-Aim2) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chemotherapy and Radioimmunotherapy CI brief — competitive landscape report
- Chemotherapy and Radioimmunotherapy updates RSS · CI watch RSS
- University of Pittsburgh portfolio CI